Munich, Germany-based neurocare group AG announced on July 22 the acquisition of Smart TMS in the United Kingdom. According to data captured in the LevinPro HC database, this acquisition represents the 40th Behavioral Health Care transaction of 2024, and the third transaction announced in the transcranial magnetic stimulations provider specialty.
Smart TMS is the largest provider of transcranial magnetic stimulation (TMS) treatment in the United Kingdom. Smart TMS operates nine clinics across the United Kingdom and Ireland. Founded in 2015, Smart TMS was a pioneer in using TMS for treating conditions like obsessive-compulsive disorder, addiction and adolescent psychiatry. TMS, a non-invasive and medication-free treatment option, has demonstrated significant efficacy in treating various psychological disorders with minimal side effects.
neurocare group provides mental health and performance by personalizing therapy following a detailed assessment through innovative technologies that help patients regain a healthier brain and better quality of life.
This acquisition expands neurocare’s clinic network and introduces its digital therapy platform for more personalized therapy. By integrating tools such as sleep assessment, psychotherapy, neurofeedback and neuromodulation technologies like TMS, neurocare aims to enhance mental healthcare individualization.
Other acquirers in the space this year have been Beacon Behavioral Partners, which acquired The Neuropsychiatry & TMS Group, and nDatalyze, which acquired Mindbalanced. Both of those deals were announced in March 2024. There were no transcranial magnetic stimulations provider deals announced during 2023, and three announced during 2022.
